Mobile

An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa 2b administered every 4 weeks plus ribavirin in interferon alfa-...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-002039-34

An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa 2b administered every 4 weeks plus ribavirin in interferon alfa-naïve patients with genotype 2/3 chronic hepatitis C

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and tolerability of up to four doses of alb-IFN Q4w (900 µg, 1200 µg, 1500 µg and possibly 1800 µg) plus daily RBV in IFNα naïve patients with genotype 2/3 CHC.

Critère d'inclusion

  • Chronic hepatitis C

Liens